GSTM5

Across TCGA pan-cancer cohorts, GSTM5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GSTM5 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GSTM5 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GSTM5 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and UCEC are the cancer types where GSTM5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.483	0.297	.002	82	view →
LUAD	DFS	Quartile	All	0.888	0.537	.007	5	view →
UCEC	OS	Quartile	II,III,IV	0.366	1.000	.016	4	view →
CCRCC	OS	Quartile	III,IV	0.915	0.536	.034	3	view →
LSCC	DFS	Quartile	II,III,IV	0.855	1.000	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GSTM5–PDAC (DFS)

Open the PDAC breakdown →